Quarterly ResultJun 18, 2026, 02:26 PM
Trinity Biotech Awarded 2M+ HIV Test Orders; Q1 Revenue +43% to $10.8M
AI Summary
Trinity Biotech announced it has been awarded significant orders for over 2 million TrinScreen HIV tests, reinforcing strong demand and supporting 2026 revenue and profitability targets. Concurrently, the company reported its Q1 2026 financial results, with revenues increasing 43% to $10.8 million, driven by strong rapid HIV and haemoglobin product sales. The company also achieved substantial year-on-year gross margin percentage improvements and significantly reduced its net loss and negative Adjusted EBITDA, reflecting progress in its Comprehensive Transformation Plan.
Key Highlights
- Trinity Biotech awarded significant orders for over 2 million TrinScreen HIV tests.
- Q1 2026 revenue increased 43% to $10.8 million from $7.6 million in Q1 2025.
- Rapid HIV sales reached $3.7 million in Q1 2026, including $2.3 million from TrinScreen HIV.
- Haemoglobin product sales rose to $3.3 million from $2.3 million in Q1 2025.
- Gross margin improved to 35.4% from 25.2% in Q1 2025, with gross profit of $3.8 million.
- Net loss narrowed to $4.4 million in Q1 2026 from $8.8 million in Q1 2025.
- Adjusted EBITDA improved to negative $1.1 million from negative $4.0 million in Q1 2025.
- Commercial scale-up of outsourced UniGold HIV production expected substantially in Q3 2026.
Price Impact
More from TRIB